Company / Current Assets
NEKTAR THERAPEUTICS Current Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$266.3M
FY2025
5-year range
$261.3M / $795.6M
FY2021-FY2025
Trend
+1.9%
vs FY2024
Sector context
#176 of 213
Health Care
What the data says
NEKTAR THERAPEUTICS's current assets of $266M is lower than 83% of companies in the Health Care sector (FY2025). Current Assets returned to growth in FY2025 after 6 years of decline, reaching $266M.
Based on SEC 10-K filings.
$266M in FY2025 with a 5-year CAGR of -25.2%.
Declined from $331M to $266M over the past 2 years.
Health Care sector context is included.
Current Assets over time
Growth rates
- 3-Year CAGR
- -21.3%
- 5-Year CAGR
- -25.2%
- 10-Year CAGR
- -
Sector benchmark
Bottom 17% in Health CareTop 83% of 213This company $266.3M Sector average $2.5B
▼
-89.4% below sector average
Key checks
Key Insights
- 5-year CAGR of -25.2%, indicating a declining trend.
- In FY2025, current assets increased 1.9% year-over-year.
- Ranks #176 out of 213 companies in the Health Care sector.
- Peak current assets was recorded in FY2018.
Company context
Key Data Points
- Altman Z-Score -11.97 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $266.3M | +1.9% |
| FY2024 | $261.3M | -21.0% |
| FY2023 | $330.7M | -39.4% |
| FY2022 | $546.0M | -31.4% |
| FY2021 | $795.6M | -30.1% |
| FY2020 | $1.1B | -19.9% |
| FY2019 | $1.4B | -1.1% |
| FY2018 | $1.4B | +339.9% |
| FY2017 | $326.8M | -23.3% |
| FY2016 | $426.3M | +21.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026